Efavirenz-rifampicin interaction: therapeutic drug monitoring to efavirenz dosage optimization in HIV/TBC patients

被引：11

作者：

Cabrera, Salvador E. ^{[1
,2
]}

Cordero, Miguel ^{[3
]}

Iglesias, Alicia ^{[3
]}

Valverde, Maria P. ^{[1
]}

Dominguez-Gil, Alfonso ^{[1
,4
]}

Garcia, Maria J. ^{[4
]}

机构：

[1] Hosp Univ Salamanca, Serv Farm, Salamanca 37007, Spain

[2] Univ Austral Chile, Inst Pharm, Valdivia, Chile

[3] Univ Hosp Salamanca, Infect Dis Serv, Salamanca, Spain

[4] Univ Salamanca, Dept Pharmaceut Technol, E-37008 Salamanca, Spain

来源：

AIDS | 2008年 / 22卷 / 18期

关键词：

D O I：

10.1097/QAD.0b013e3283189c07

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

引用

页码：2549 / 2551

页数：3

共 7 条

[1]

[Anonymous], GUID US ANT AG HIV 1

[2]

Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1

[3]

JOLY V, 1999, AIDS REV, V1, P37

[4] Validation of a simplified medication adherence questionnaire in a large cohort of HIV-infected patients:: the GEEMA Study [J].

Knobel, H ;

Alonso, J ;

Casado, JL ;

Collazos, J ;

González, J ;

Ruiz, I ;

Kindelan, JM ;

Carmona, A ;

Juega, J ;

Ocampo, A .

AIDS, 2002, 16 (04) :605-613

[5] Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients [J].

Marzolini, C ;

Telenti, A ;

Decosterd, LA ;

Greub, G ;

Biollaz, J ;

Buclin, T .

AIDS, 2001, 15 (01) :71-75

[6]

SOY D, 2005, 6 INT WORKSH CLIN PH

[7]

2004, MMWR, V53, P37

← 1 →